Overview

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Status:
Completed

Trial end date:
2019-10-31

Target enrollment:

Participant gender:

Summary

Anetumab ravtansine is developed for the treatment of patients with recurrent platinum-resistant ovarian cancer. The purpose of the proposed trial is to identify the maximum tolerated dose of anetumab ravtansine that could be safely combined with pegylated liposomal doxorubicin in this indication.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Doxorubicin
Immunoconjugates
Liposomal doxorubicin
Maytansine